Thrombosis Service

HomeThrombosis ResearchBibliographies

Bibliographies

  • Pendleton RC, Wheeler M, Wanner N, Strong M, Vinik R, and Peters C. A Safe, effective, and easy to use warfarin initiation dosing nomogram for post-joint arthroplasty patients. J Arthoplasty. 2010 January; 25(1): 121-7.
  • Lenzini P, Wadelius M, Kimmel S, …Pendleton RC , Berg RL, Deloukas P, and Gage BF. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharm Therapeutics. 2010; 87(5):572-8.
  • McMillin GA, Melis R, Wilson A, Strong MB, Wanner NA, Vinik RG, Peters CL, and Pendleton RC. Gene-based warfarin dosing compared to standard of care practices in an orthopedic surgery population: a prospective, parallel cohort Study. Ther Drug Monitoring. (2010) 32(3): 338-45.
  • Pollack CV, Schrieber D, Goldhaber SZ, Fanikos J, O'Neil BJ, Thompson JR, Hiestand B, Briese BA, Pendleton RC, Miller CD, Kline JA. Clinical Characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the Emergency Department: Initial report of the multicenter emergency medicine pulmonary embolism in the real world registry (EMPEROR).  JACC (2010).  Accepted for Publication (May 2010).
  • Rondina MT, Wheeler M, Rodgers, GM, Draper L, Pendleton RC. Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medially-ill patients. Thromb Res 2010 Mar; 125(3): 220-3, PMC19272635.
  • Vasquez SR, Johnson SA, Rondina MT. Peri-procedural anticoagulation in patients undergoing ablation for atrial fibrillation. Thrombosis Research 2010 Aug; 126(2): e69-77, PMC20053426.
  • Rondina MT, Walker A, Pendleton RC. Drug-induced thrombocytopenia for the hospitalist physician with a focus on heparin-induced thrombocytopenia. Hosp Pract (Minneap) 2010 Apr; 38(2): 19-28, PMC20469610.
  • Franks ZG, Campbell RC, Weyrich AS, Rondina MT. Platelet-leukocyte interactions link inflammatory and thromboembolic events in ischemic stroke.  New York Academy of Sciences 2010 Oct;1207:11-7.
  • Freeman A, Pendleton RC, Rondina MT. The prevention of venous thromboembolism in morbid obesity. Expert Reviews of Cardiovascular Therapy 2010;8(12):1711-21.
  • Piazza G , Rosenbaum EJ, Pendergast, W, Jacobson JO, Pendelton RC,  McLaren GD, Elliott CG, Stevens SM, Patton WF, Dabbagh O, Paterno MD, Catapane E, Li Z, MD, Goldhaber SZ. Physician Alerts to Prevent Deep Vein Thrombosis and Pulmonary Embolism in Hospitalized Patients. Circulation. 2009; 119(16): 2196-201.
  • Vinik R, Wanner N, and Pendleton RC. Peri-procedural anti-thrombotic management: a review of the literature and practical approach for the hospitalist physician. J Hosp Med. November 2009; 4(9):551-9.
  • Pendleton RC, Rodgers GM, and Hull RD. Established venous thromboembolism therapies: heparin, low molecular weight heparins, and vitamin K antagonists with a discussion of heparin induced thrombocytopenia. Clin Chest Med. 2010 Dec;31(4):691-706.
  • Vazquez SR, Freeman A, VanWoerkom RC, Rondina MT. Contemporary issues in the prevention and management of post-thrombotic syndrome. Ann Pharmacother 2009 Nov; 43(11): 1824-35, PMC19737994.
  • Rondina M, Pendleton R, Wheeler M and Rodgers G. The treatment of venous thromboembolism in special populations. Thrombosis Research. 2007; 119: 391-402.
  • Pendleton, R. Blood Issues: Anticoagulation Management of Special Populations. Audio-digest. General Surgery. Feb 2007. Volume 54(Issue 03).
  • Rondina, MT, Rodgers, GM, Nohavec R, Markewitz BA. The Accuracy of Activated Partial Thromboplastin Times when Drawn Through a Peripherally Inserted Central Catheter. Am J Hematology 2007 Aug; 82(8):738-9.
  • Schwertz H, Tolley ND, Foulks JM, Denis MM, Rondina MT, Harris EM, Kraiss LW, Zimmerman GA, Weyrich AS. Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenicity of human platelets. J Exp Med 2006 Oct 30;203(11):2433-40.
  • Pendleton RC, Wheeler, M and Rodgers G. Argatroban Dosing of Patients With Heparin-Induced Thrombocytopenia and an Elevated Baseline APTT Due to Antiphospholipid Antibody Syndrome- A Single Institution Case Series. Annals of Pharmacotherapy. May 2006; 40:972-976.
  • Creekmore F, Pendleton RC, et al. The Incidence and Economic Implications of Heparin Induced Thrombocytopenia when Preventing Venous Thrombosis in Medical Patients. Pharmacotherapy 2006; 26(10): 1438-1445.
  • Pendleton RC and Rodgers GM. An Unusual case in the diagnosis and management of acute pulmonary embolism. A J Med 2006; 119(8): 651-653.
  • Pendleton, R. Issues in Coagulation: A practical approach to peri-procedural anticoagulation. Audio-digest. General Surgery. Aug 2006.53(15).
  • Pendleton, R. Issues in Coagulation: The must knows of heparin-induced thrombocytopenia. Audio-digest. General Surgery. Aug 2006.53(15).
  • Rondina MT, Muhlestein JB. Initiation of Statin Therapy for Acute Coronary Syndromes: A Review of the Evidence. Journal of Interventional Cardiology 2005;18(1):55-63
  • Stinnett J, Pendleton R, Skordos L, Wheeler M, Rodgers G.. Venous Thromboembolism Prophylaxis in Medically Ill Patients and the Development of Strategies to Improve Prophylaxis Rates. A J Hematology2005; 78:167-17
  • Pendleton, R, Wheeler, M and Rodgers G. Venous Thromboembolism Prevention in the Acutely-Ill Medical Patient: A Review of the Literature and Focus on Special Patient Populations. A J Hematology July 2005; 79:229-237.
  • Fiessenger et al.  For the THRIVE Treatment Study Investigators. A double blind safety and efficacy study of the Oral Direct Thrombin Inhibitor, H376/95 versus standard therapy [Enoxaparin and Warfarin] in patients with Acute Symptomatic Deep venous thrombosis with or without Pulmonary Embolism. JAMA 2005; 293: 681 – 689
  • Zebrack JS, Rondina MT. Clinical Study: Achieving National Cholesterol Education Program Goals in Coronary Artery Disease. Prev Cardiol. 2005 Winter;8(1):18-22